Literature DB >> 2498642

Effects of organic and inorganic Ca antagonists on rat platelet arachidonic acid metabolism in the presence of Ca2+, Sr2+ and Ba2+.

D Blache1, M Ciavatti.   

Abstract

The effects of Ca-antagonists on the thrombin-induced mobilization of radiolabeled arachidonate preincorporated into rat platelets as well as the subsequent formation of labeled cyclooxygenase and lipoxygenase products were analyzed in the presence of either Ca2+ or Ca2+-substitutes, Sr2+ and Ba2+. Results indicate that following thrombin stimulation (0.2 U/ml) in the presence of Ca2+, nitrendipine (Nit), Cd2+ or Mn2+ reduced the release of arachidonate and the biosynthesis of thromboxane B2. Inhibition of arachidonic acid release and metabolism were also obtained by both Nit and Cd2+ in the presence of Sr2+ and Ba2+. Results from studies with a semi-purified phospholipase A2 fraction prepared from rat platelets indicated that the activity was almost unaffected by Nit or Cd2+. From these findings, we concluded that inhibition of platelet-induced release and metabolism of arachidonic acid by the Ca-antagonists tested require intact platelets. These data support the hypothesis of an interaction of these agents at an unknown surface membrane level.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2498642     DOI: 10.1007/bf00577114

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  23 in total

1.  Rat platelet arachidonate metabolism in the presence of Ca2+, Sr2+ and Ba2+: studies using intact platelets and semi-purified phospholipase A2.

Authors:  D Blache; M Ciavatti
Journal:  Biochim Biophys Acta       Date:  1987-10-17

2.  Effects by nifedipine on thromboxane synthesis in vitro and in vivo.

Authors:  G Davì; S Novo; M Fiore; A Foderà; A Mattina; A Mazzola; A Strano
Journal:  Thromb Res       Date:  1982-12-15       Impact factor: 3.944

3.  Effects of nifedipine (Adalat) on platelet function in vitro and in vivo.

Authors:  H Johnsson
Journal:  Thromb Res       Date:  1981 Feb 15-Mar 1       Impact factor: 3.944

4.  Nifedipine, diltiazem, bepridil and verapamil uptakes into cardiac and smooth muscles.

Authors:  D C Pang; N Sperelakis
Journal:  Eur J Pharmacol       Date:  1983-02-18       Impact factor: 4.432

5.  Effect of cations on the blood platelet release reaction.

Authors:  J M Sneddon; K I Williams
Journal:  J Physiol       Date:  1973-12       Impact factor: 5.182

6.  Verapamil decreases the formation of thromboxane from exogenous 14C-arachidonic acid in human platelets in vitro.

Authors:  M L Dahl; P Uotila
Journal:  Prostaglandins Leukot Med       Date:  1985-02

7.  Inhibition of human platelet functions by verapamil.

Authors:  Y Ikeda; M Kikuchi; K Toyama; K Watanabe; Y Ando
Journal:  Thromb Haemost       Date:  1981-04-30       Impact factor: 5.249

8.  Verapamil suppresses atherosclerosis in cholesterol-fed rabbits.

Authors:  J L Rouleau; W W Parmley; J Stevens; J Wikman-Coffelt; R Sievers; R W Mahley; R J Havel
Journal:  J Am Coll Cardiol       Date:  1983-06       Impact factor: 24.094

9.  15-hydroxy-5,8,11,13-eicosatetraenoic acid: A potent and selective inhibitor of platelet lipoxygenase.

Authors:  J Y Vanderhoek; R W Bryant; J M Bailey
Journal:  J Biol Chem       Date:  1980-07-10       Impact factor: 5.157

10.  Responses to adenosine diphosphate in human platelets loaded with the fluorescent calcium indicator quin2.

Authors:  T J Hallam; T J Rink
Journal:  J Physiol       Date:  1985-11       Impact factor: 5.182

View more
  2 in total

1.  Phospholipase D activation by P2Z-purinoceptor agonists in human lymphocytes is dependent on bivalent cation influx.

Authors:  C E Gargett; E J Cornish; J S Wiley
Journal:  Biochem J       Date:  1996-01-15       Impact factor: 3.857

2.  Influence of a long-term zinc-deficient diet on rat platelet function and fatty acid composition.

Authors:  P Faure; P Durand; D Blache; A Favier; A M Roussel
Journal:  Biometals       Date:  1995-01       Impact factor: 2.949

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.